Exhibit 99.1

                                                COMPANY CONTACT:

                                                Cindy Presar, Investor Relations
                                                cpresar@cardiodynamics.com
                                                800-778-4825 Ext. 1031

             CARDIODYNAMICS ANNOUNCES SENIOR MANAGEMENT APPOINTMENTS

SAN DIEGO, CA--December 9, 2005--CardioDynamics (Nasdaq: CDIC), the innovator
and leader of Impedance Cardiography (ICG) technology, today announced the
appointment of Donald Brooks to the position of Chief Technology Officer and
Kevin Hammond to the position of Vice President of Sales. Mr. Brooks will
oversee the product development and research activities of the Company, and Mr.
Hammond will oversee the Company's U.S. field sales operations.

"We are pleased to have these highly respected and experienced managers join our
senior management team," stated Michael K. Perry, Chief Executive Officer of
CardioDynamics. "Together, Don and Kevin bring solid track records of success to
their new positions and will drive key growth initiatives to maximize the
potential of our innovative ICG technology."

Brooks has over 23 years of product development experience at Hewlett Packard,
Siemens Medical Systems, Inc., and several start-up medical technology
companies. Most recently, he served as CardioDynamics' Vice President of Product
Development and oversaw the BioZ Dx development. Don has a B.S. in Electrical
Engineering and an M.S. in Engineering from North Carolina State University.

Hammond has 15 years of experience with increasing roles of responsibility
including the past six years at CardioDynamics. Most recently, he led the
Company's top-producing sales region for 2005. Kevin has a B.A. in Political
Science from San Diego State University and an M.B.A. from the Keller Graduate
School of Business Administration. With the promotion of Hammond, the company
has realigned its regional sales structure to strengthen the clinical and
application knowledge of its direct sales team while reducing its reliance on
distribution partners.

The Company also announced that Dennis Hepp will be retiring from full-time
service as its Chief Technology Officer at the end of December. Perry stated,
"We are grateful for the tremendous contribution that Dennis has made as our
Chief Technology Officer for the past nine years. He has led our research and
development teams that brought to market three generations of impedance
cardiography systems and our proprietary BioZtect(R) sensors. We wish him the
very best in his return to full-time consulting at Rivertek Medical and also
greatly appreciate his willingness to support us in that capacity in 2006."



ABOUT CARDIODYNAMICS:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The Company
develops, manufactures and markets noninvasive diagnostic and monitoring
technologies and electrodes. The Company's ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women--cardiovascular disease. Partners include GE Healthcare and Philips
Medical Systems. For additional information, please refer to the company's Web
site at www.cdic.com.

FORWARD-LOOKING (SAFE HARBOR) STATEMENT:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, such as success of growth
initiatives and maximizing ICG potential, the accuracy of which is necessarily
subject to uncertainties and risks including the Company's sole dependence on
the BioZ product line, and various uncertainties characteristic of early growth
companies, as well as other risks detailed in the Company's filings with the
SEC, including its 2004 Form 10-K/A. The Company does not undertake to update
the disclosures contained in this press release.